10x Genomics (TXG) Expected to Announce Quarterly Earnings on Thursday

10x Genomics (NASDAQ:TXG) will likely be announcing its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $160.3520 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 4:30 PM ET.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.05. The firm had revenue of $149.00 million during the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.30) earnings per share. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

NASDAQ TXG opened at $19.06 on Thursday. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $23.56. The stock has a market capitalization of $2.41 billion, a PE ratio of -30.74 and a beta of 2.24. The business’s 50-day moving average is $18.64 and its 200 day moving average is $15.37.

Insider Activity

In related news, insider Benjamin J. Hindson sold 8,283 shares of the business’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $19.00, for a total transaction of $157,377.00. Following the sale, the insider owned 432,605 shares of the company’s stock, valued at $8,219,495. The trade was a 1.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Serge Saxonov sold 13,261 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the completion of the sale, the chief executive officer owned 1,021,556 shares in the company, valued at approximately $19,409,564. This trade represents a 1.28% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 33,432 shares of company stock worth $635,208. Corporate insiders own 9.39% of the company’s stock.

Institutional Trading of 10x Genomics

Institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning raised its stake in shares of 10x Genomics by 3.0% during the 3rd quarter. Creative Planning now owns 56,874 shares of the company’s stock worth $665,000 after acquiring an additional 1,637 shares in the last quarter. CANADA LIFE ASSURANCE Co boosted its stake in 10x Genomics by 14.9% in the third quarter. CANADA LIFE ASSURANCE Co now owns 25,365 shares of the company’s stock valued at $287,000 after acquiring an additional 3,296 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in 10x Genomics by 203.9% in the second quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after purchasing an additional 5,025 shares during the last quarter. Legal & General Group Plc increased its position in shares of 10x Genomics by 5.0% during the third quarter. Legal & General Group Plc now owns 116,378 shares of the company’s stock worth $1,360,000 after purchasing an additional 5,514 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of 10x Genomics by 30.5% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,392 shares of the company’s stock valued at $309,000 after purchasing an additional 6,162 shares during the last quarter. 84.68% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TXG. UBS Group lifted their price objective on 10x Genomics from $13.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Needham & Company LLC set a $21.00 price target on shares of 10x Genomics in a report on Monday, January 12th. Leerink Partners reduced their price objective on shares of 10x Genomics from $22.00 to $20.00 and set a “market perform” rating on the stock in a research report on Tuesday, January 27th. TD Cowen restated a “hold” rating on shares of 10x Genomics in a report on Wednesday, January 7th. Finally, Morgan Stanley reaffirmed an “equal weight” rating and set a $20.00 target price (up previously from $17.00) on shares of 10x Genomics in a research note on Monday, December 1st. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $16.83.

10x Genomics Company Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.